{
  "context": {
    "rules": [
      "Rule1: Either organization1 uses substance1 or drug1 provides a successful treatment.",
      "Rule2: Provided that drug1 is effective, then whenever drug1 treats disease1, it results in a successful treatment.",
      "Rule3: In case drug1 is in phase1 trial, then it is also in phase3 trial.",
      "Rule4: Drug1 is in phase1 trial or drug1 is in phase2 trial.",
      "Rule5: Whenever drug1 is in phase2 trial, it implies that drug1 is effective.",
      "Rule6: Given that drug1 is FDA approved, then if drug1 is in phase3 trial, drug1 is effective.",
      "Rule7: Provided that organization6 is licensed, then organization6 produces drug2.",
      "Rule8: Organization6 is licensed or organization7 imports drug2.",
      "Rule9: In the event that region2 has approved drug2, then drug1 provides a successful treatment.",
      "Rule10: Should region1 have banned material1, then organization1 does not use substance1.",
      "Rule11: Whenever the FDA monitors drug3, then if it is not the case that imports by organization7 lead to approval by region2, drug2 is counterfeit.",
      "Rule12: Provided that the FDA investigates organization8, then the FDA monitors drug3.",
      "Rule13: The FDA investigates organization8 or the FDA audits organization9.",
      "Rule14: Given that the FDA issued a warning letter to organization8, then whenever the FDA audits organization9, the FDA monitors drug3.",
      "Rule15: Either the FDA issued a warning letter to organization8 or the FDA is conducting an inspection of organization9.",
      "Rule16: Should the FDA be conducting an inspection of organization9, then if the FDA audits organization9, the FDA monitors drug3.",
      "Rule17: Whenever manufacturer1 recalls drug4, then if drug1 does not provide a successful treatment, drug4 does not have side effects.",
      "Rule18: In case manufacturer1 admits fault, then manufacturer1 settles lawsuit1.",
      "Rule19: Manufacturer1 admits fault or manufacturer1 denies fault.",
      "Rule20: Should manufacturer1 deny fault, then if contamination does not imply non-defectiveness, patient1 filed a lawsuit against manufacturer1.",
      "Rule21: Provided that company1 extends the patent for drug5, then if it is not the case that patenting leads to successful treatment, a generic version of drug5 is not available.",
      "Rule22: In the event that company1 innovates drug6, then should company1 not extend the patent for drug5, company2 does not compete with drug5.",
      "Rule23: Whenever company1 acquires company3, then if company1 does not extend the patent for drug5, company2 does not compete with drug5.",
      "Rule24: Provided that company1 researches disease2, then either company1 innovates drug6 or company1 acquires company3.",
      "Rule25: In case region3 has restricted material3, then region1 has not approved material1.",
      "Rule26: Should company4 violate regulation1, then company4 is compliant.",
      "Rule27: Whenever company4 violates regulation1, then company4 is fined.",
      "Rule28: Given that agency1 investigates company4, then if company4 is fined, company4 is not compliant.",
      "Rule29: Agency1 investigates company4 or agency2 audits company4.",
      "Rule30: Provided that agency1 revokes the license of company4, then if agency2 audits company4 and company4 is fined, company4 is not compliant.",
      "Rule31: Either agency1 revokes the license of company4 or agency2 suspends the license of company4.",
      "Rule32: In case agency2 suspends the license of company4, then if agency2 audits company4 and company4 is fined, company4 is not compliant.",
      "Rule33: Whenever drug7 is experimental, then drug7 is not an approved therapy.",
      "Rule34: In the event that organization2 develops material2, then organization4 tests material2.",
      "Rule35: Organization2 develops material2 or organization3 imports material2.",
      "Rule36: Should drug7 be expensive, then insurance1 does not cover drug7.",
      "Rule37: Medicare reimburses for drug7 or, if drug7 is not experimental, then drug7 is expensive.",
      "Rule38: Provided that the FDA rejected drug8, then Medicare does not reimburse for drug7.",
      "Rule39: Company5 litigates against the FDA or company5 appeals decision1 or, if company5 resubmits drug8, then whenever contamination does not imply non-defectiveness, patient1 filed a lawsuit against manufacturer1.",
      "Rule40: In case company5 withdraws drug8, then company5 does not litigate against the FDA.",
      "Rule41: Company5 develops an alternative, drug9 or, provided that company5 does not withdraw drug8, then company5 does not continue research on drug8.",
      "Rule42: Should organization3 import material2, then if it is not the case that banning by region1 implies non-approval by region1, material1 is not safe.",
      "Rule43: Whenever drug10 is successful, then drug10 is profitable.",
      "Rule44: Drug10 is relaunched or, if it is not the case that blockbuster status implies success and then niche status, then drug10 is discontinued.",
      "Rule45: Provided that organization4 tests material2, then organization5 manufactures material2.",
      "Rule46: Whenever organization5 manufactures material2, then if it is not the case that banning by region1 implies non-approval by region1, material1 is not safe.",
      "Rule47: Should contamination not imply non-defectiveness, then patient1 did not file a lawsuit against manufacturer1.",
      "Rule48: Whenever it is not the case that patenting leads to successful treatment, then a generic version of drug5 is available.",
      "Rule49: Should it not be true that blockbuster status leads to success, then drug10 is not niche.",
      "Rule50: Provided that it is not the case that non-patenting implies non-generic availability, then drug10 is a blockbuster.",
      "Rule51: In the event that it is not the case that non-banning by region1 leads to restriction by region3, then company4 violates regulation1.",
      "Rule52: Provided that it is not true that non-banning implies non-approval by region1, then material1 is safe.",
      "Rule53: Should drug1 not be effective, then drug7 is an approved therapy.",
      "Rule54: In case region1 has not banned material1, then region1 has approved material1.",
      "Rule55: Should manufacturer1 not recall drug4, then drug4 is defective.",
      "Rule56: In the event that manufacturer1 does not recall drug4, then drug4 is contaminated.",
      "Rule57: Whenever company1 does not extend the patent for drug5, then company2 competes with drug5.",
      "Rule58: Should drug7 not be experimental, then insurance1 covers drug7.",
      "Rule59: In the event that company5 does not withdraw drug8, then company5 continues research on drug8.",
      "Rule60: Provided that drug1 does not provide a successful treatment, then drug4 has side effects."
    ],
    "facts": [
      "Fact1: Drug1 is FDA approved.",
      "Fact2: Drug5 is patented.",
      "Fact3: Company1 researches disease2.",
      "Fact4: The FDA rejected drug8.",
      "Fact5: Company5 resubmits drug8.",
      "Fact6: Drug1 treats disease1.",
      "Fact7: Organization6 does not produce drug2.",
      "Fact8: Drug2 is not counterfeit.",
      "Fact9: Manufacturer1 does not settle lawsuit1.",
      "Fact10: Company5 does not appeal decision1.",
      "Fact11: Company5 does not develop an alternative, drug9.",
      "Fact12: Drug10 is not profitable.",
      "Fact13: Drug10 is not discontinued.",
      "Fact14: Drug10 is not relaunched."
    ]
  },
  "question": "Drug1 provides a successful treatment."
}